Clinical Trials

Clinical Trial Number: NSABP B55

Treatment trial for patients diagnosed with germline BRCA 1/2 mutations and high-risk HER2 negative breast cancer

Eligibility Criteria

  • Must be 18 years or older
  • Must have triple negative breast cancer defined as one of the following:
    • ER and PgR negative and HER2 negative (not eligible for anti-HER2 therapy)
    • ER and/or PgR positive, HER2 negative
  • Must have documented germline mutation in the genes BRCA1 or BRCA2 that is known or predicted to be detrimental (leading to loss of function)
  • Must have completed breast and axilla surgery, and at least six cycles of adjuvant or neoadjuvant chemotherapy

Additional criteria may apply.

Give feedback
Your input is valuable to us.
Please take a moment to share your feedback about your experience on our website today.